Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | CES2 | O00748 | 2/20 | 0.48 |
| ▸ | CES1 | P23141 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | TSPO | P30536 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toluene SCHEMBL27587127 | 0.87 | LMNA (0.58) | LMNATSHRALOX12ACHECES2 | |
| P-Xylene SCHEMBL6214884 | 0.87 | ALDH1A1 (0.50) | LMNATSHRACHECES2CES1 | |
| Toluene SCHEMBL9815765 | 0.84 | LMNA (0.69) | LMNATSHRALOX12ACHECES2 | |
| Toluene SCHEMBL19715122 | 0.84 | LMNA (0.69) | LMNATSHRALOX12ACHECES2 | |
| Toluene SCHEMBL10799413 | 0.84 | LMNA (0.69) | LMNATSHRALOX12ACHECES2 | |
| Toluene SCHEMBL10941235 | 0.84 | LMNA (0.69) | LMNATSHRALOX12ACHECES2 | |
| Toluene SCHEMBL9689391 | 0.84 | LMNA (0.69) | LMNATSHRALOX12ACHECES2 | |
| Toluene SCHEMBL5776784 | 0.84 | LMNA (0.69) | LMNATSHRALOX12ACHECES2 | |
| Toluene SCHEMBL10604374 | 0.84 | LMNA (0.69) | LMNATSHRALOX12ACHECES2 | |
| Toluene SCHEMBL9176449 | 0.84 | LMNA (0.69) | LMNATSHRALOX12ACHECES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059165-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI (FR) | 2012-03-08 | — | — | US | claimed |
| EP-2406254-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI (FR) | 2012-01-18 | — | — | EP | claimed |
| WO-2010104193-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-16 | — | — | WO | claimed |
| US-20090203915-A1 | Process for the preparation of solifenacin | DIPHARMA FRANCIS S.R.L. (IT) | 2009-08-13 | — | — | US | claimed |
| EP-2088148-A2 | \"Process for the preparation of solifenacin\ | Dipharma Francis S.r.l. (IT) | 2009-08-12 | — | — | EP | claimed |
| CN-115215886-A | Compounds and compositions as endosomal Toll-like receptor inhibitors | 诺华股份有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-109641899-B | Compounds and compositions as endosomal Toll-like receptor inhibitors | 诺华股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-3510033-B1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS AG (CH) | 2021-11-24 | — | — | EP | disclosed |
| US-20210101902-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS AG (CH) | 2021-04-08 | — | — | US | disclosed |
| US-10954233-B2 | Compounds and compositions as inhibitors of endosomal toll-like receptors | NOVARTIS AG (CH) | 2021-03-23 | — | — | US | disclosed |
| US-10815227-B2 | Processes for the preparation of filgotinib | CADILA HEALTHCARE LIMITED (IN) | 2020-10-27 | — | — | US | disclosed |
| US-20200062744-A1 | PROCESSES FOR THE PREPARATION OF FILGOTINIB | CADILA HEALTHCARE LIMITED (IN) | 2020-02-27 | — | — | US | disclosed |
| EP-0845464-A2 | S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds as intermediates for camptothecin derivatives | TANABE SEIYAKU CO., LTD. (JP) | 1998-06-03 | — | — | EP | disclosed |
| WO-1993025521-A1 | ARYL ALIPHATIC ACIDS | BOARD OF GOVERNORS OF WAYNE STATE UNIVERSITY (US) | 1993-12-23 | — | — | WO | disclosed |
| US-5231329-A | Organic thin film electroluminescent device | NIPPON OIL CO., LTD. (JP) | 1993-07-27 | — | — | US | disclosed |
| US-5166283-A | Polymers for use in electronic components and semiconductors | HITACHI LTD. (JP) | 1992-11-24 | — | — | US | disclosed |
| EP-0295381-A1 | Polymer having dihydropyridine rings or dihydrotriazine rings, process for producing the same, and applications thereof | HITACHI, LTD. (JP) | 1988-12-21 | — | — | EP | disclosed |
| EP-0130270-B1 | EPOXY COMPOSITIONS CONTAINING OLIGOMERIC DIAMINE HARDENERS AND HIGH STRENGTH COMPOSITES THEREFROM | AMOCO CORPORATION (US) | 1987-07-29 | — | — | EP | disclosed |
| US-4608404-A | Epoxy compositions containing oligomeric diamine hardeners and high strength composites therefrom | UNION CARBIDE CORPORATION (US) | 1986-08-26 | — | — | US | disclosed |
| EP-0130270-A1 | Epoxy compositions containing oligomeric diamine hardeners and high strength composites therefrom | AMOCO CORPORATION (US) | 1985-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059165-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | HRH4, HNMT, CYP3A4 | LMNA 2935/4885TSHR 510/4885ALOX12 3530/4885 |
| US-10815227-B2 | Processes for the preparation of filgotinib | ABL1, FER, FLNA | LMNA 2131/4885TSHR 1637/4885ALOX12 986/4885 |
| US-20200062744-A1 | PROCESSES FOR THE PREPARATION OF FILGOTINIB | ABL1, FER, FLNA | LMNA 2131/4885TSHR 1637/4885ALOX12 986/4885 |
| US-20210101902-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | TLR3, TLR1, TLR4 | LMNA 2514/4885TSHR 1798/4885ALOX12 3446/4885 |
| US-20090203915-A1 | Process for the preparation of solifenacin | OPRL1, CHRNE, OPRK1 | LMNA 2712/4885TSHR 1564/4885ALOX12 4801/4885 |
| US-10954233-B2 | Compounds and compositions as inhibitors of endosomal toll-like receptors | TLR3, TLR1, TLR4 | LMNA 2514/4885TSHR 1798/4885ALOX12 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.